APHINITY: thelancet.com/journals/lanon…
CATALINA: thelancet.com/journals/lanon…
NSABP B-41: nature.com/articles/s41523-0…
7
Our thanks to the many authors and investigators behind these studies, and above all to the patients and their families who took part in these trials. Without them, none of this is possible.
1
10
-In addition, NSABP B-41 (out in npj Breast Cancer): 262 patients from the phase III neoadjuvant HER2-positive trial. Case45's spatial TME metrics independently predicted both pathologic complete response and event-free survival, irrespective of ER status.
1
15
Both Lancet Oncology studies are reports of the International Immuno-Oncology Biomarker Working Group.
1
11
Three tested AI biomarkers were independently prognostic for invasive disease-free, distant disease-free, and overall survival after adjustment for clinicopathological factors.
1
9
vs 89.8% in concordantly immune-low tumors.
-CATALINA (The Lancet Oncology): 1,356 patients with early triple-negative breast cancer pooled from seven phase III randomized adjuvant trials (BIG 2-98, ECOG-ACRIN E1199 and E2197, FinHER, IBCSG 22-00, PACS 01, and PACS 04).
1
22
(IDFS HR 0.46 vs HR 0.86). AI scoring by Case45 reclassified 11.6% of node-positive tumors from manually-scored immune-low to immune-high, a subgroup in which the pertuzumab–placebo separation in 5-year invasive disease-free survival widened to 92.5% vs 87.5%, compared with 90.0%
1
16
-APHINITY (The Lancet Oncology): 4,262 patients from the phase III adjuvant pertuzumab trial, median follow-up 74 months. Case45's AI biomarkers were prognostic for invasive disease-free survival. Greater pertuzumab benefit was identified in AI-defined immune-high vs low tumors
1
17
Case45’s model provides orthogonal and explainable tumor microenvironment biology from routine histology slides, and was never trained, fine-tuned, or threshold-optimized on a single patient from any of the nine studies.
1
14
The studies below span 5,880 patients across nine phase III randomized controlled trials in early breast cancer, HER2-positive and triple-negative disease, neoadjuvant and adjuvant settings.
1
22

